0000950170-24-001197.txt : 20240103 0000950170-24-001197.hdr.sgml : 20240103 20240103173040 ACCESSION NUMBER: 0000950170-24-001197 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240101 FILED AS OF DATE: 20240103 DATE AS OF CHANGE: 20240103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEONARD JOHN M CENTRAL INDEX KEY: 0001563584 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37766 FILM NUMBER: 24508332 MAIL ADDRESS: STREET 1: C/O INTELLIA THERAPEUTICS INC STREET 2: 40 ERIE STREET, SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER NAME: FORMER CONFORMED NAME: LEONARD JOHN M. DATE OF NAME CHANGE: 20121204 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intellia Therapeutics, Inc. CENTRAL INDEX KEY: 0001652130 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364785571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-285-6200 MAIL ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 ownership.xml 4 X0508 4 2024-01-01 0001652130 Intellia Therapeutics, Inc. NTLA 0001563584 LEONARD JOHN M C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET; SUITE 130 CAMBRIDGE MA 02139 true true false false President and CEO false Common Stock 2024-01-01 4 M false 7848 A 865709 D Common Stock 58415 I By Trust Restricted Stock Unit 2024-01-01 4 M false 7848 0 D 2024-01-01 2031-03-02 Common Stock 7848 7850 D Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Shares held by the John M. Leonard 2015 Irrevocable Trust. On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. James Basta, attorney-in-fact 2024-01-03